NEW YORK, March 16, 2023 (GLOBE NEWSWIRE) – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) investigates claims on behalf of investors of LivePerson, Inc. (“LivePerson” or the “Company”) LPSN.

If you would like to discuss our investigation, please contact us via email pmayer@kaplanfox.com or by calling (646) 315-9003, or Click here.

On February 28, 2023, LivePerson filed a Form 12b-25 Late Filing Notice stating that it was unable to file its Form 10-K for the year ended December 31, 2022 within the required time Deadline without undue effort or expense, as it requires additional time to complete a revenue review related to a recently discontinued program at its subsidiary WildHealth (the “Program”) and to complete the ongoing review of internal controls and procedures. Following the news, LivePerson shares fell $1.69 per share, about 14.3%, to close at $10.12 per share.

On March 6, 2023, LivePerson announced in a Form 8-K filed with the SEC that its review of WildHealth “is expected to impact fourth-quarter 2022 revenue attributable to WildHealth’s participation in a Medicare demonstration program because Medicare refunds under the program were suspended pending further regulatory review in November 2022.” Following the news, shares of LivePerson fell more than 21% over the next six trading days to close at $9.02 per share on March 13, 2023 .

Then, on March 15, 2023, LivePerson issued a post-launch press release reporting fourth quarter 2022 financial results, including a decline in revenue and a loss of revenue for the fourth quarter. In addition, the company announced that “[w]Although the Company currently believes that the services rendered under the program were valid in the fourth quarter of 2022, given the inherent uncertainty as to the timing and amount of further reimbursements for services rendered under the program, the Company has elected a reserve for revenue related to services …